Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Total Current Liabilities (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Total Current Liabilities readings, the most recent being $2.1 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 19.66% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a 19.66% decrease, with the full-year FY2025 number at $2.1 million, down 19.66% from a year prior.
  • Total Current Liabilities hit $2.1 million in Q4 2025 for Arcadia Biosciences, down from $2.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $7.7 million in Q2 2021 to a low of $1.8 million in Q2 2025.
  • Median Total Current Liabilities over the past 5 years was $4.0 million (2022), compared with a mean of $3.9 million.
  • Biggest five-year swings in Total Current Liabilities: crashed 40.08% in 2024 and later decreased 1.85% in 2025.
  • Arcadia Biosciences' Total Current Liabilities stood at $5.0 million in 2021, then fell by 16.49% to $4.2 million in 2022, then dropped by 14.71% to $3.6 million in 2023, then dropped by 28.61% to $2.6 million in 2024, then fell by 19.66% to $2.1 million in 2025.
  • The last three reported values for Total Current Liabilities were $2.1 million (Q4 2025), $2.3 million (Q3 2025), and $1.8 million (Q2 2025) per Business Quant data.